BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors. 2021

Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.

Aberrant activation of the fibroblast growth factor 19-fibroblast growth factor receptor 4 (FGF19-FGFR4) signaling pathway has been proved to promote hepatocellular carcinoma (HCC) proliferation. It is assumed that the first FGFR4 inhibitor BLU9931 did not enter clinical studies, presumably due to its rapid metabolism in liver microsomes. Here, we report the development of series of quinazoline derivatives based on FGFR4 inhibitor BLU9931 through structural modification of its solvent region pocket to minimize its potential metabolic liability. Among them, compound 35a exhibited comparable or superior kinase inhibitory activity (IC50 = 8.5 nM) and selectivity in cells. More importantly, compound 35a improved liver microsomes stability compared to BLU9931. Cellular mechanistic studies demonstrated that 35a induced apoptosis via the FGFR4 signaling pathway blockage. In addition, the computational simulation revealed the possible binding mode to FGFR4 protein, which provides a plausible explanation of high potent and metabolic stability.

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
May 2023, Bioorganic & medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
March 2021, European journal of medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors.
January 2024, Bioorganic chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.
January 2019, Mini reviews in medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
March 2024, European journal of medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors.
May 2024, Bioorganic & medicinal chemistry letters,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
February 2022, Journal of medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors.
February 2019, European journal of medicinal chemistry,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors.
July 2012, ChemMedChem,
Chenghao Pan, and Wenwen Nie, and Jiao Wang, and Jiamin Du, and Zhichao Pan, and Jian Gao, and Yang Lu, and Jinxin Che, and Hong Zhu, and Haibin Dai, and Binhui Chen, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
November 2023, Bioorganic chemistry,
Copied contents to your clipboard!